https://biopharmaperspective.com/2026/08/22/johnson-johnson-wins-eu-approval-for-tecvayli-plus-darzalex-in-multiple-myeloma/ 2026-08-22T00:48:55Z Biopharma Perspective en Johnson & Johnson Wins EU Approval for Tecvayli Plus Darzalex in Multiple Myeloma 2026-08-22T00:48:53Z Blog https://biopharmaperspective.com/2026/08/22/two-different-ways-to-fight-multiple-myeloma/ 2026-08-22T00:49:35Z Biopharma Perspective en Two Different Ways to Fight Multiple Myeloma 2026-08-22T00:47:41Z Blog https://biopharmaperspective.com/2026/08/21/regeneron-wins-fda-approval-for-pasatru-in-ultra-rare-bone-disease/ 2026-08-21T10:35:13Z Biopharma Perspective en Regeneron Wins FDA Approval for Pasatru in Ultra-Rare Bone Disease 2026-08-21T10:35:11Z Blog https://biopharmaperspective.com/2026/08/21/how-pasatru-blocks-abnormal-bone-formation-in-fop/ 2026-08-21T10:36:12Z Biopharma Perspective en How Pasatru Blocks Abnormal Bone Formation in FOP 2026-08-21T10:30:06Z Blog https://biopharmaperspective.com/2026/08/20/how-modernas-personalized-mrna-cancer-therapy-trains-the-immune-system/ 2026-08-20T10:04:16Z Biopharma Perspective en How Moderna’s Personalized mRNA Cancer Therapy Trains the Immune System 2026-08-20T10:04:15Z Blog https://biopharmaperspective.com/2026/08/20/modernas-personalized-mrna-cancer-therapy-delivers-first-phase-3-win/ 2026-08-20T10:04:40Z Biopharma Perspective en Moderna’s Personalized mRNA Cancer Therapy Delivers First Phase 3 Win 2026-08-20T10:01:22Z Blog